Anzeige
Meldung des Tages: Diese Zahlen lügen nicht: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Ionis Pharmaceuticals News

Aktie
WKN:  A2ACMZ ISIN:  US4622221004 US-Symbol:  IONS Branche:  Biotechnologie Land:  USA
64,14 €
+0,42 €
+0,66%
17.04.26
Depot/Watchlist
Marktkapitalisierung *
10,79 Mrd. €
Streubesitz
-
KGV
-47,75
Nachhaltigkeits-Score
52 %
Index-Zuordnung
Nasdaq Composite Index
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,69: MM4376
Werbung

Ionis Pharmaceuticals News

10.04.26 wallstreetONLINE Redaktion
Bristol Myers, Merck oder Jazz: Die besten Pharma-Aktien für die Quartalssaison
US-​Pharmaaktien haben den Markt zuletzt klar geschlagen – doch genau das macht sie anfällig. Bank of America nennt 4 Favoriten für die Quartalssaison und erklärt, warum Zölle ...
10.01.26 - WH Selfinvest
IonQ Aktie 2026: Hype oder echte Chance im Quantum-Computing-Markt?
Aktuelle Analysen, Perspektiven und Charttechnik der IonQ Aktie.
09.10.25 - ARIVA.DE Redaktion
JPMorgan ist bei dieser Biotech-Aktie bullish
JPMorgan stuft die Aktien von Ionis Pharmaceuticals mit "Übergewichten" ein und sieht dank einer vielversprechenden Medikamentenpipeline großes Potenzial. Das Kursziel wurde ...
13.01.25 - PR Newswire
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
Ionis enters new chapter in 2025 as commercial-​stage biotech with multiple independent product launches anticipated and continued late-​stage pipeline momentum PR Newswire
08.01.25 - PR Newswire
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
19.12.24 - PR Newswire
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
TRYNGOLZA™ (olezarsen) approved in U.S. as first-​ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet PR Newswire
07.11.24 - PR Newswire
Ionis to present at upcoming investor conferences
Ionis to present at upcoming investor conferences PR Newswire
06.11.24 - PR Newswire
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome PR Newswire
06.11.24 - PR Newswire
Ionis reports third quarter 2024 financial results
Ionis reports third quarter 2024 financial results PR Newswire
04.11.24 - PR Newswire
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE PR Newswire
23.10.24 - PR Newswire
Ionis to hold third quarter 2024 financial results webcast
Ionis to hold third quarter 2024 financial results webcast PR Newswire
21.10.24 - PR Newswire
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-​mediated amyloidosis ...
03.10.24 - PR Newswire
New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting PR Newswire
01.10.24 - PR Newswire
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease PR Newswire
09.09.24 - PR Newswire
Ionis announces pricing of $500.3 million public offering
Ionis announces pricing of $500.3 million public offering PR Newswire
28.08.24 - PR Newswire
Ionis to present at upcoming investor conferences
Ionis to present at upcoming investor conferences PR Newswire
01.08.24 - PR Newswire
Ionis reports second quarter 2024 financial results
Ionis reports second quarter 2024 financial results PR Newswire
31.07.24 - PR Newswire
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen ...
22.07.24 - PR Newswire
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire
19.07.24 - PR Newswire
Ionis to hold second quarter 2024 financial results webcast
Ionis to hold second quarter 2024 financial results webcast PR Newswire

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »